4.7 Article

Norcantharidin potentiates sorafenib antitumor activity in hepatocellular carcinoma rat model through inhibiting IL-6/STAT3 pathway

Journal

TRANSLATIONAL RESEARCH
Volume 260, Issue -, Pages 69-82

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.trsl.2023.05.005

Keywords

cancer stemness; demethylcantharate; drug resistance; epithelial mesenchymal transition; hepassocin; hypoxia-inducible factor 1 alpha; interleukin-6; liver cancer; tumor microenvironment; oxidative stress

Ask authors/readers for more resources

This study evaluates the ability of norcantharidin (NCTD) to improve the efficacy of sorafenib (Sora) in hepatocellular carcinoma (HCC). The results show that NCTD enhances the activity of Sora against HCC and potentiates Sora-induced oxidative stress, tumor immunity reactivation, and attenuation of angiogenesis and metastasis. NCTD also suppresses drug resistance and stemness, and boosts Sora's antiproliferative and apoptotic activities.
In hepatocellular carcinoma (HCC), sorafenib (Sora) efficacy is limited by primary and/or acquired resistance. Emerging evidence shows that the inflammatory factor interleukin 6 (IL-6) plays a role in Sora resistance. Norcantharidin (NCTD), a derivative of cantharidine, was identified as a potent IL-6 inhibitor. Thus, in this study, we evaluated NCTD ability to improve the Sora efficacy in HCC and its underlying molecular mechanisms. Male Sprague Dawely rats were administered NCTD (0.1 mg/kg/day; orally) or Sora (10 mg/kg day; orally) or combination for 6 weeks after HCC induction using thioacetamide (200 mg/kg; ip; 2 times/wk) for 16 weeks. Our results showed that NCTD greatly enhanced Sora activity against HCC and potentiated Sora-induced oxidative stress. NCTD enhanced Sora-induced tumor immunity reactivation by decreasing both fibrinogen-like protein 1 level and increasing both tumor necrosis factor-& alpha; gene expression along with CD8+ T cells number. Also, NCTD augmented Sora attenuation activity against TAA-induced angiogenesis and metastasis by decreasing VEGFA, HIF-1 & alpha;, serum lactate dehydrogenase enzyme, and vimentin levels. The combined use of NCTD/Sora suppressed drug resistance and stemness by downregulating ATP binding cassette subfamily G member 2, neurogenic locus notch homolog protein, spalt-like transcription factor 4, and CD133. NCTD boosted Sora antiproliferative and apoptotic activities by decreasing Ccnd1 and BCL2 expressions along with increasing BAX and caspase-3 expressions. To our knowledge, this study represents the first study providing evidence for the potential novel therapeutic use of NCTD/Sora combination for HCC. Moreover, no previous studies have reported the effect of NCTD on FGL1.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available